載入...
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial
IMPORTANCE: Current treatment options for progressive ovarian cancer provide limited benefit, particularly in patients whose disease has become resistant to platinum-based chemotherapy. OBJECTIVE: To assess the efficacy and safety of avelumab, an anti–programmed death-ligand 1 agent, in a cohort of...
Na minha lista:
| 發表在: | JAMA Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Medical Association
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6439837/ https://ncbi.nlm.nih.gov/pubmed/30676622 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.6258 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|